critical care medicine and anesthesiology

For patients with lymphoma, multiple myeloma, or certain types of leukemia, treatment with chimeric antigen receptor T cells (CAR T cells) is sometimes the last chance of overcoming the cancer. The treatment involves taking T cells from the patient's blood and adding artificial receptors – the CARs – to them in the lab. As the guards of our immune system, T cells are on permanent patrol in our blood vessels and tissues, where they hunt down foreign structures. Equipped with CARs, T cells can also detect very specific surface structures on cancer cells. Once the CAR T cells are returned to the patient by infusion, docotorate in traditional and complemtary medicine they circulate in the body as a kind of living drug that can bind to very specific tumor cells and destroy them.

The engineered immune cells remain in the body permanently and multiply. If the cancer flares up again, they'll go back into action. That's the theory, at least. But in practice, many patients still relapse. This is because the tumor cells can outwit the CAR T cells by producing more of the protein EBAG9 – and by causing the T cells to produce more of it, too. In T cells, EBAG9 inhibits the release of cytotoxic enzymes, which slows the desired immune response.

A month earlier, a team led by last authors Dr. Armin Rehm and Dr. Uta Höpken from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) showed in the journal JCI Insight that shutting down the EBAG9 gene in mice led to a sustained increase in the immune response to cancer. The mice also developed more T memory cells. These cells are part of our immunological memory, which allows our immune system to respond better to a cancer antigen after encountering it previously.

Now the researchers have also shown these key findings in vitro, in human CAR T cells. Writing in Molecular Therapy, the team says that this is the decisive step on the road to therapeutic use. "Shutting down EBAG9 allows the body to eradicate tumor cells earlier and more radically. As well as achieving longer-lasting therapeutic success, this could also create a real chance of cure," says Rehm.

Releasing the brake for immunotherapy

As soon as the EBAG9 gene was discovered, researchers recognized that it played an important role in cancer. But it took a long time to identify what that role actually was. When the MDC team started working on it in 2009, they found that mice without the gene dealt with bacterial and viral infections much better than mice with the gene, and that they formed more T memory cells, which are of particular interest in tumor biology.

Then in 2015, lead author Dr. Anthea Wirges succeeded in curbing synthesis of the EBAG9 protein using microRNA. For the latest study, she used microRNA to cultivate "EBAG9-silenced" CAR T cells with different human leukemia or lymphoma cells. Just like in the mouse model, the silencing reduced tumor growth much more. Relapses also only developed much later.

"Releasing the EBAG9 brake allows the genetically engineered T cells to release more cytotoxic substances. However, they don't cause the strong cytokine storm that is typically a side effect of CAR therapy," says Wirges. In fact, the risk is minimized because fewer cells are used. "Switching off the immune brake works across the board. We can do it with every CAR T cell that we produce – regardless of which type of blood cancer it targets.

Clinical studies are the next step

However, the first-line therapy for blood cancer will remain chemotherapy combined with conventional antibody therapy, as many patients respond very well to this. "CAR therapy only comes into play if the cancer returns. It's very expensive because it's an individual cellular product for a single person," says Höpken. And a single treatment with that product can save a life.

The EBAG9 work shows how important perseverance and patience are for researchers. Wirges was motivated by the prospect of her work having a real chance of clinical application. Rehm adds: "Projects like this allow you to get to grips with a technique in basic research and then apply everything in translational research – right up to toxicological screening for the regulatory processes." Their project has now reached this last stage: The researchers will present their concept to the Paul Ehrlich Institute, Germany's biologics approval agency, in November.

Thanks to their findings from animal models and the in vitro experiments using human cells, the team now knows that releasing the EBAG9 brake is highly effective and doesn't cause any more side effects than conventional CAR T therapy. "We now need bold clinicians and a partner for financing the clinical studies," says Rehm. If everything goes well, the therapy using EBAG9-silenced CAR T cells could be available to patients in as little as two years' time.z Association

Source:

Max Delbrück Center for Molecular Medicine in the Helmholtz Association

Journal reference:

Anthea Wirges et al. (2022): "EBAG9-silencing exerts an immune checkpoint function without aggravating adverse effects." Molecular Therapy, DOI: 10.1016/j.ymthe.2022.07.009

Posted in: Medical Research News | Medical Condition News

Tags: Antibody, Antigen, Blood, Blood Cancer, Blood Vessels, Cancer, Cell, Chemotherapy, Chimeric Antigen Receptor, Cytokine, Electron, Gene, Immune Response, Immune System, Immunotherapy, in vitro, Leukemia, Lymphocyte, Lymphoma, Medicine, Micrograph, MicroRNA, Molecular Biology, Mouse Model, Multiple Myeloma, Myeloma, Protein, Receptor, Research, T Lymphocyte, Tumor

Comments (0)

Source: Read Full Article